We presented the results on the efficacy of RCI001 in sécheresse oculaire.
The drug demonstrated superior efficacy in comparison with existing drugs, generating strong expectations for its potential success.
RudaCure is actuellement proceeding with GMP production of the drug and is targeting FDA essai clinique entry in 2023.